0,06 $
24,72 %
Nasdaq, Fr, 23.02.2024
ISIN
CH0346177709
Symbol
OBSV
Berichte
Sektor
Industrie

ObsEva SA Aktie News

Neutral
GlobeNewsWire
26 Tage alt
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 31 January 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it was granted a temporary moratorium (sursis provisoire) by the competent court in Geneva, Switzerland.
Neutral
GlobeNewsWire
3 Monate alt
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – November 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that, following a comprehensive assessment of the company's financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Sw...
Neutral
GlobeNewsWire
4 Monate alt
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   Geneva, Switzerland – October 27, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that XOMA will be receiving full worldwide rights on ebopiprant, an investigational, orally active, selective prostaglandin F2α (PGF2α) receptor antagonist, following the ...
Neutral
GlobeNewsWire
5 Monate alt
ObsEva Files half Year 202 3 Financial Statements
Neutral
GlobeNewsWire
8 Monate alt
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland –  Ju ly 13 , 202 3  – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it has recovered full worldwide rights on nolasiban, a novel, oral oxytocin receptor antagonist being developed to improve clinical pregnancy and live birth rates in ...
Neutral
GlobeNewsWire
8 Monate alt
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – June 30 , 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that shareholders approved all Board proposals at its 2023 Annual General Meeting held on June 29, 2023.
Neutral
GlobeNewsWire
9 Monate alt
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland –  June 8 , 202 3  – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today published the invitation to its 2023 Annual General Meeting of Shareholders to be held on June 29, 2023, at 10:30 CEST at the company's offices in Geneva, Chemin des Aulx 12, 3rd floo...
Neutral
GlobeNewsWire
10 Monate alt
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – May 2 , 202 3 – ObsEva SA ( SIX: OBSN ), a biopharmaceutical company developing novel therapies for women's health, today announced that Fabien de Ladonchamps has been appointed Chief Executive Officer effective May 1, 2023.
Mehr News anzeigen

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen